Phenomenex Chiral Screening Services Now Offered in China
News Dec 05, 2012
Phenomenex Inc. has announced the extension of its Chiral Screening Service to pharmaceutical and natural products customers in China.
The service is offered in collaboration with the Chinese Academy of Sciences (CAS), a leading academic and R&D center under which the Shanghai Institute of Organic Chemistry (SIOC) has developed a strong chiral team that works closely with Phenomenex.
The free Chiral Screening Service provides target screening using a library of HPLC columns including the Phenomenex Lux™ polysaccharide-based offerings, which demonstrate a success rate approaching 90 percent.
After resolving the chiral compound, Phenomenex delivers a method development and optimization plan to the customer within 10 business days - the same rapid turnaround the service promises in the U.S. and Europe.
“Our customer base in China has been growing rapidly and the expansion of our services will help us better serve them,” explains Michael Klein, brand manager for Phenomenex. “By teaming up with the CAS-SIOC, we are able to quickly roll out our rapid-response service.”
Enantiomers of chiral compounds may have different pharmacological effects in biological systems and they must be identified and evaluated separately.
“Resolving chiral compounds is relatively difficult, and column selection can be complicated,” continues Klein. “Our Chiral Screening Service eliminates time-consuming guesswork and also gives customers a chance to ‘test-drive’ our Lux columns.”
The Phenomenex team of chiral experts will customize a plan for each screening project, taking into account specific requirements and overall separation goals.
Once a project is completed, the customer will receive a report that details the optimal method including information on the chiral stationary phase (CSP) selected for the separation, running conditions and associated chromatograms.
Research Team Discovers Compound that Stops Cancer From SpreadingNews
Using a mouse model, OHSU physician-scientists lead effort to hone a drug that inhibits cancer cells from spreading to other areas in the body.READ MORE
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
The Friedrich Schiller University Jena Partners with ACD/Labs to Advance its Analytical Data Management StrategyNews
Implementation of ACD/Spectrus as an analytical data management system helps researchers and students streamline NMR and MS data processing, interpretation, collaboration, and training.READ MORE